CSF2 and congenital rubella syndrome: In preclinical models, GM-CSF neutralization reduced myeloid cell-derived inflammatory cytokines and ameliorated CRS and ICANS, and IL-1 inhibition reduced macrophage activity and abolished CRS and ICANS symptoms.